CSNK2A1 and acute myeloid leukemia: We also selected drugs (nilotinib, acalabrutinib, and fostamatinib) that block LYN, CSNK2A1, and SYK proteins, which were the most enriched in the EVs derived from the AML cells, to evaluate their potential clinical applications.